Targeting monocyte recruitment in CNS autoimmune disease

Clinical Immunology

Volumn 103, Issue 2, 2002, Pages 125-131

  Izikson, Leonid ^a   Klein, Robyn S ^b   Luster, Andrew D ^b   Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CCR2; Chemotaxis; EAE; MCP 1; Monocyte; MS; Treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLOPIPERIDINE; LIGAND; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ANTAGONIST; OLIGOPEPTIDE[51-62]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIPERIDINE DERIVATIVE; POLYPEPTIDE; POLYPEPTIDE[9-76]; RECEPTOR BLOCKING AGENT; RETINOID X RECEPTOR; SPIROPIPERIDINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTAXIS; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY DISEASE; KNOCKOUT MOUSE; MACROPHAGE; MONOCYTE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0036267183     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5167     Document Type: Article

References (61)

1. Autoimmune diseases
2. Tolerance and autoimmunity
3. The Dale E. McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion
4. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
5. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system
6. Multiple sclerosis
7. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR) 2
8. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis
9. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis
10. Chemokines - Chemotactic cytokines that mediate inflammation
11. Chemokines and leukocyte traffic
12. Monocyte chemoattractant protein-1
13. CCR2: From cloning to the creation of knockout mice
14. Characterization of the CCR2 chemokine receptor: Functional CCR 2 receptor expression in B cells
15. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions
16. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions
17. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1 and IP-10 are expressed in demyelinating brain lesions
18. Monocyte activation in multiple sclerosis
19. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis
20. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1
21. Kinetics and cellular origin of cytokines in the central nervous system: Insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis
22. Chemokine expression in murine experimental allergic encephalomyelitis
23. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis
24. Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis
25. Assessment of animal models for MS and demyelinating disease in the design of rational therapy
26. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis
27. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
28. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
29. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
30. Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death
31. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients
32. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma
33. Chemokine regulation of experimental autoimmune encephalomyelitis: Temporal and spatial expression patterns govern disease pathogenesis
34. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice
35. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines
36. Animal models
37. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1
38. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
39. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice
40. A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: Role of CCR 2 in linking the innate and adaptive immune responses
41. Inflammatory chemokine transport and presentation in HEV: A remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues
42. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking
43. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo
44. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro
45. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells
46. Chemokines and T lymphocyte activation. I. Beta chemokines costimulate human T lymphocyte activation in vitro
47. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production
48. Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1
49. Cultured rat micro glia express functional beta-chemokine receptors
50. Immune regulation within the central nervous system
51. Blocking chemokine receptors
52. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal
53. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model
54. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: Binding to a chemokine receptor motif within the helical bundle
55. CCR2B receptor antagonists: Conversion of a weak HTS hit to a potent lead compound
56. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists
57. Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines
58. Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes
59. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
60. Inhibition of monocyte chemotactic protein-1 synthesis by statins
61. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis